Literature DB >> 19883377

Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I.

Cinzia Tesauro1, Paola Fiorani, Ilda D'Annessa, Giovanni Chillemi, Gino Turchi, Alessandro Desideri.   

Abstract

The interaction of human topoisomerase I and erybraedin C, a pterocarpan purified from the plant Bituminaria bituminosa, that was shown to have an antitumour activity, was investigated through enzymatic activity assays and molecular docking procedures. Erybraedin C is able to inhibit both the cleavage and the religation steps of the enzyme reaction. In both cases, pre-incubation of the drug with the enzyme is required to produce a complete inhibition. Molecular docking simulations indicate that, when interacting with the enzyme alone, the preferential drug-binding site is localized in proximity to the active Tyr723 residue, with one of the two prenilic groups close to the active-site residues Arg488 and His632, essential for the catalytic reaction. When interacting with the cleavable complex, erybraedin C interacts with both the enzyme and DNA in a way similar to that found for topotecan. This is the first example of a natural compound able to act on both the cleavage and religation reaction of human topoisomerase I.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19883377     DOI: 10.1042/BJ20091127

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  8 in total

1.  Phenolic composition, enzyme inhibitory, and antioxidant activity of Bituminaria bituminosa.

Authors:  Cengiz Sarikurkcu; Mustafa Cengiz; Mehmet Cemil Uren; Olcay Ceylan; Tuba Orenc; Bektas Tepe
Journal:  Food Sci Biotechnol       Date:  2016-10-31       Impact factor: 2.391

2.  From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge Dendrilla antarctica.

Authors:  Alessio Ottaviani; Joshua Welsch; Keli Agama; Yves Pommier; Alessandro Desideri; Bill J Baker; Paola Fiorani
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Development of derivatives of 3, 3'-diindolylmethane as potent Leishmania donovani bi-subunit topoisomerase IB poisons.

Authors:  Amit Roy; Sayan Chowdhury; Souvik Sengupta; Madhumita Mandal; Parasuraman Jaisankar; Ilda D'Annessa; Alessandro Desideri; Hemanta K Majumder
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

Review 4.  Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.

Authors:  Chetan Kumar Jain; Hemanta Kumar Majumder; Susanta Roychoudhury
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

Review 5.  Natural products as new antimitotic compounds for anticancer drug development.

Authors:  Carlos Roberto Koscky Paier; Sarah Sant'Anna Maranhão; Teiliane Rodrigues Carneiro; Lídia Moreira Lima; Danilo Damasceno Rocha; Renan da Silva Santos; Kaio Moraes de Farias; Manoel Odorico de Moraes-Filho; Claudia Pessoa
Journal:  Clinics (Sao Paulo)       Date:  2018-12-10       Impact factor: 2.365

Review 6.  Systematic Review of Potential Anticancerous Activities of Erythrina senegalensis DC (Fabaceae).

Authors:  Souleymane Fofana; Moussa Ouédraogo; Rafaèle Calvo Esposito; Windbedema Prisca Ouedraogo; Cédric Delporte; Pierre Van Antwerpen; Véronique Mathieu; Innocent Pierre Guissou
Journal:  Plants (Basel)       Date:  2021-12-22

Review 7.  Topoisomerase IB: a relaxing enzyme for stressed DNA.

Authors:  Bini Chhetri Soren; Jagadish Babu Dasari; Alessio Ottaviani; Federico Iacovelli; Paola Fiorani
Journal:  Cancer Drug Resist       Date:  2020-03-19

8.  A small organic compound enhances the religation reaction of human topoisomerase I and identifies crucial elements for the religation mechanism.

Authors:  Barbara Arnò; Andrea Coletta; Cinzia Tesauro; Laura Zuccaro; Paola Fiorani; Sara Lentini; Pierluca Galloni; Valeria Conte; Barbara Floris; Alessandro Desideri
Journal:  Biosci Rep       Date:  2013-03-07       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.